KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $444.1 million.

  • Halozyme Therapeutics' Income towards Parent Company rose 27.89% to $175.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 51.72%. This contributed to the annual value of $444.1 million for FY2024, which is 57.71% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Income towards Parent Company of $444.1 million as of FY2024, which was up 57.71% from $281.6 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Income towards Parent Company registered a high of $444.1 million during FY2024, and its lowest value of $129.1 million during FY2020.
  • Over the past 3 years, Halozyme Therapeutics' median Income towards Parent Company value was $281.6 million (recorded in 2023), while the average stood at $309.3 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Income towards Parent Company surged by 278.69% in 2020, and later slumped by 49.81% in 2022.
  • Halozyme Therapeutics' Income towards Parent Company (Yearly) stood at $129.1 million in 2020, then surged by 211.97% to $402.7 million in 2021, then tumbled by 49.81% to $202.1 million in 2022, then skyrocketed by 39.31% to $281.6 million in 2023, then skyrocketed by 57.71% to $444.1 million in 2024.